GlassScriptPhysician profile
Jaclyn West Bates
NPI 1184994238
$4,304.39
in general payments reported to CMS, 2019-2025
33 companies · $713 in 2025
The $713 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,129 · 2022: $776 · 2023: $762 · 2024: $924 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $741.78 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $651.88 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.71 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $362.83 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $300.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $276.11 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Preventric Diagnostics, INC. | $197.23 | 2021 | |
| Pfizer INC. | $149.37 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.00 | 2021-2022 | |
| Exact Sciences Corporation | $120.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $119.52 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $113.87 | 2021-2023 | |
| Mylan Specialty L.P. | $92.79 | 2022-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $81.63 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.65 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $52.62 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $50.18 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $43.23 | 2022-2023 | Quviviq |
| Daiichi Sankyo INC. | $38.73 | 2021 | |
| Merck Sharp & Dohme LLC | $38.01 | 2021-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Biohaven Pharmaceutical Holding Company LTD. | $36.73 | 2022 | |
| Amarin Pharma, INC. | $32.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.38 | 2021-2023 | Xarelto |
| Corcept Therapeutics | $29.89 | 2024-2025 | Korlym |
| Vanda Pharmaceuticals INC. | $24.75 | 2025 | Fanapt |
| Abbott Laboratories | $24.19 | 2021 | |
| Viatris Specialty LLC | $22.84 | 2025 | Yupelri |
| Eisai INC. | $14.96 | 2021 | |
| Esperion Therapeutics, INC. | $14.59 | 2025 | Nexletol |
| Amgen INC. | $14.12 | 2024 | Prolia, Evenity |
| E.R. Squibb & Sons, L.L.C. | $13.24 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.97 | 2021 | |
| Organon LLC | $10.23 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.